Company intelligence / Profile preview

Shanghai Dahua Pharmaceutical

Shanghai, Shanghai, China

Ownership: Private
Employees: ~100
Development stage: Other

Overview

Shanghai Dahua Pharmaceutical is the global manufacturer of the WHO prequalified subdermal contraceptive implant Sino-implant (II) (branded as Levoplant), providing a long-acting, reversible contraceptive using levonorgestrel. The implant is registered in over 30 countries, with clinical and post-marketing data showing high efficacy and safety. The company has become the third global supplier in the segment after MSD and Bayer, improving access to affordable contraception in low- and middle-income countries.[3][5][6][7][10]

Therapeutic areas: Women's Health
Modalities: Small molecule
Industry: Biotech

Partnerships

United Nations Population Fund (UNFPA)United States Agency for International Development (USAID)

Beyond the preview

Go deeper on Shanghai Dahua Pharmaceutical.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Shanghai Dahua Pharmaceutical.

Explore the full profile